about
Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.Iron-chelating and anti-lipid peroxidation properties of 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) in long-term iron loading β-thalassemic mice.Targeting chelatable iron as a therapeutic modality in Parkinson's disease.Deferiprone challenge test for monitoring iron overload in hepatitis positive thalassemic major patients.Advances in iron chelation: an update.The oral iron chelator deferiprone protects against iron overload-induced retinal degenerationPopulation pharmacokinetics of deferiprone in healthy subjects.Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial.On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure.Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retinaLiver Enzymes in Children with beta-Thalassemia Major: Correlation with Iron Overload and Viral Hepatitis.Deferiprone-induced agranulocytosis: 20 years of clinical observations.Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone.β-Thalassemia.Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years.Frequency of neutropenia among Turkish and Syrian pediatric thalassemia patients under deferiprone monotherapy.Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis.Skin Disorders in Egyptian Children with β-Thalassemia Major.Zinc Status in Beta Thalassemia Major Patients.
P2860
Q33411923-9890C6A4-A651-4195-A76D-FB2197CF7A61Q33682055-FF09BF63-FB0D-436E-A57F-F742772A6500Q33768106-172BBED7-5A70-4783-A99E-C44C3BEA5906Q33951185-E78FF0FD-0091-4FF1-B26D-429480F2CF0DQ34174307-2E4068D5-655B-4804-A46F-90308EE9CC0EQ34281402-8B32A146-981B-4046-B407-68BFB76E8A8EQ34635568-43D360B4-06A2-4B4A-B1DB-D28D64AD914CQ34941788-B9307092-E2D3-4555-AEBF-72760336FB24Q35232747-D2D2B8AE-D60F-4508-A807-7A00CE6B77D3Q36050418-266BEC74-D03E-4198-9460-A16E222E768DQ36929351-59DDE88B-C99B-4CC6-8786-A26624F9A6F7Q37456259-70067D96-6CE2-4A4F-B7B1-84C676BFAB40Q37762809-DBF220DB-66BF-4DE5-AE7D-0060C9685BFDQ38998151-578094ED-E1CC-42AF-9A3B-EDD96D2C435CQ39377048-140CAE27-31F4-4819-A5B6-C1C7B6663614Q40776444-F519B5AB-E9E7-4F89-A984-81A7251ED640Q42601757-0D123E64-CF41-425B-BB96-AF27678F90DEQ46853343-7DD691F4-74C3-4B28-BB7A-B1EBCF587862Q47371612-BC6240B3-B612-4555-AAF6-9325B58604ABQ49906370-6A7B7646-7395-4D48-B59D-D37315880F6D
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Deferiprone chelation therapy for thalassemia major.
@ast
Deferiprone chelation therapy for thalassemia major.
@en
type
label
Deferiprone chelation therapy for thalassemia major.
@ast
Deferiprone chelation therapy for thalassemia major.
@en
prefLabel
Deferiprone chelation therapy for thalassemia major.
@ast
Deferiprone chelation therapy for thalassemia major.
@en
P356
P1433
P1476
Deferiprone chelation therapy for thalassemia major.
@en
P2093
P304
P356
10.1159/000243800
P577
2009-11-10T00:00:00Z